抗コクシジウム薬市場 - 世界の産業規模、シェア、動向、機会、予測：薬剤クラス別、薬剤作用別、動物タイプ別、流通チャネル別、地域別、競合、2019-2029年

抗コクシジウム薬の世界市場規模は2023年に13億4,000万米ドルとなり、2029年までのCAGRは3.86%で、予測期間中に着実な成長が予測されています。

世界の抗コクシジウム薬市場は、家畜衛生産業の中でもダイナミックで急速に発展している分野であり、世界の畜産物需要の高まりと、家禽、牛、豚、その他の動物におけるコクシジウム症の持続的な脅威がその原動力となっています。コクシジウム症は、Eimeria属の原虫寄生によって引き起こされ、生産性の低下、罹患率、死亡率によって畜産業に大きな経済的損失をもたらします。その結果、抗コクシジウム薬市場は、集約的農法の採用の増加、食品の安全性と動物福祉に対する懸念の高まり、コクシジウムの薬剤耐性株の出現に後押しされ、大幅な成長を遂げています。市場の主要企業は、有効性、安全性プロファイル、様々な生産システムへの適合性を改善した新規製剤を導入するための研究開発活動への投資を続けています。

バイオテクノロジーと分子生物学の進展により、コクシジウム防除のためのワクチン、プロバイオティクス、酵素などの代替戦略の開発が促進され、市場競争が激化しています。地理的には、北米と欧州が世界の抗コクシジウム薬市場を独占していますが、これは畜産農場が集中していること、動物の健康を管理する規制が厳しいこと、研究開発に多額の投資が行われていることによる。しかし、アジア太平洋は、畜産セクターの拡大、可処分所得の増加、畜産における予防医療措置の利点に関する意識の高まりにより、今後数年間で大きな成長が見込まれます。さらに、現在進行中のCOVID-19パンデミックは、畜産におけるバイオセキュリティと疾病予防の重要性を浮き彫りにし、抗コクシジウム薬やその他の動物用医薬品の需要を高めています。

規制上の制約、抗菌薬耐性への懸念、有機農法や持続可能な農法への移行が、市場成長への課題となっています。世界の競合情勢は、技術の進歩、消費者の嗜好の進化、競争が激化する農業の現場における動物の健康と生産性を向上させるという持続的なニーズによって後押しされ、市場は継続的に拡大する構えです。

市場促進要因

畜産製品に対する需要の高まり

コクシジウム症の流行増加

医薬品開発における技術の進歩

主な市場課題

規制上の制約

抗菌剤耐性に対する懸念

抗コクシジウム薬に代わる新たな選択肢

主要市場動向

世界の集約農業の拡大

動物の健康と福祉の重視

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 VOC (顧客の声)

第5章 世界の抗コクシジウム薬市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 薬剤クラス別（イオノフォア、抗生物質、スルホンアミド、化学誘導体、その他）
  • 薬剤作用別（コクシジウム抑制、コクシジウム性）
  • 動物タイプ別（家畜、コンパニオンアニマル）
  • 流通チャネル別（動物病院、小売薬局、その他）
  • 地域別
  • 企業別（2023）
• 市場マップ
  • 薬剤クラス別
  • 薬物作用別
  • 動物タイプ別
  • 流通チャネル別
  • 地域別

第6章 アジア太平洋地域の抗コクシジウム薬市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 薬剤クラス別
  • 薬物作用別
  • 動物タイプ別
  • 流通チャネル別
  • 国別
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第7章 欧州の抗コクシジウム薬市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 薬剤クラス別
  • 薬物作用別
  • 動物タイプ別
  • 流通チャネル別
  • 国別
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第8章 北米の抗コクシジウム薬市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 薬剤クラス別
  • 薬物作用別
  • 動物タイプ別
  • 流通チャネル別
  • 国別
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第9章 南米の抗コクシジウム薬市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 薬剤クラス別
  • 薬物作用別
  • 動物タイプ別
  • 流通チャネル別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの抗コクシジウム薬市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 薬剤クラス別
  • 薬物作用別
  • 動物タイプ別
  • 流通チャネル別
  • 国別
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • エジプト

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第13章 世界の抗コクシジウム薬市場：SWOT分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 競合情勢

• Vetoquinol SA
• Zoetis Philippines Inc
• Phibro Animal Health Corporation
• Huvepharma, Inc
• Elanco US Inc.
• Biochem Pharmaceutical Industries Ltd
• Ceva Sante Animale SA
• Impextraco NV
• Boehringer Ingelheim International GmbH
• Merck & Co., Inc.

第16章 戦略的提言

第17章 調査会社について・免責事項

Global Anticoccidial Drugs Market was valued at USD 1.34 Billion in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 3.86% through 2029. The global anticoccidial drugs market is a dynamic and rapidly evolving sector within the animal health industry, driven by the escalating demand for livestock products worldwide and the persistent threat of coccidiosis in poultry, cattle, swine, and other animals. Coccidiosis, caused by protozoan parasites of the genus Eimeria, poses significant economic losses to the livestock industry due to reduced productivity, morbidity, and mortality rates. As a result, the market for anticoccidial drugs has witnessed substantial growth, propelled by the increasing adoption of intensive farming practices, rising concerns over food safety and animal welfare, and the emergence of drug-resistant strains of coccidia. Key players in the market continue to invest in research and development activities to introduce novel formulations with improved efficacy, safety profiles, and compatibility with various production systems.

Advancements in biotechnology and molecular biology have facilitated the development of alternative strategies such as vaccines, probiotics, and enzymes for coccidiosis control, thereby intensifying competition within the market. Geographically, North America and Europe dominate the global anticoccidial drugs market owing to the high concentration of livestock farms, stringent regulations governing animal health, and substantial investments in research and development. However, Asia-Pacific is anticipated to witness significant growth in the coming years, driven by the expansion of the livestock sector, increasing disposable incomes, and growing awareness regarding the benefits of preventive healthcare measures in animal production. Moreover, the ongoing COVID-19 pandemic has underscored the importance of biosecurity and disease prevention in livestock farming, thereby accentuating the demand for anticoccidial drugs and other veterinary pharmaceuticals.

The regulatory constraints, concerns over antimicrobial resistance, and the shift towards organic and sustainable farming practices pose challenges to market growth. The global anticoccidial drugs market is poised for continued expansion, fueled by technological advancements, evolving consumer preferences, and the persistent need to enhance animal health and productivity in an increasingly competitive agricultural landscape.

Key Market Drivers

Escalating Demand for Livestock Products

The escalating demand for livestock products is a significant factor driving the growth of the global anticoccidial drugs market. As the world's population continues to grow, so does the demand for animal-derived products such as meat, dairy, and eggs. This increasing demand has led to the expansion of intensive farming practices, where large numbers of animals are raised in confined spaces to meet the growing need for protein-rich food sources.

The intensification of livestock production also brings with it challenges, including a higher risk of disease outbreaks such as coccidiosis. Coccidiosis is a parasitic disease caused by protozoan parasites of the genus Eimeria, which infect the intestinal tract of poultry, cattle, swine, and other animals, leading to reduced productivity and economic losses for farmers.

To meet the rising demand for livestock products while mitigating the risks posed by diseases like coccidiosis, farmers increasingly rely on anticoccidial drugs to protect the health and productivity of their animals. These drugs work by controlling the growth and spread of coccidia in the intestines, thereby reducing the severity of the disease and its impact on livestock performance.

The growing awareness among farmers about the importance of disease prevention and biosecurity measures has further fueled the demand for anticoccidial drugs. Farmers recognize the need to safeguard their animals against diseases that can compromise their health and productivity, and anticoccidial drugs offer an effective means of achieving this goal.

The intensification of livestock production has led to a greater emphasis on maximizing efficiency and profitability. Anticoccidial drugs play a crucial role in achieving these objectives by helping to maintain optimal growth rates, feed conversion ratios, and overall performance in livestock. By controlling coccidiosis and reducing the incidence of disease-related losses, these drugs enable farmers to achieve higher yields and better returns on their investment.

The escalating demand for livestock products is driving increased utilization of anticoccidial drugs in the global market. As the need for protein-rich food sources continues to grow, the demand for effective disease control measures such as anticoccidial drugs is expected to remain strong, driving further growth and innovation in the global anticoccidial drugs market.

Rising Prevalence of Coccidiosis

The rising prevalence of coccidiosis is a significant driver behind the growth of the global anticoccidial drugs market. Coccidiosis is a parasitic disease caused by various species of the protozoan parasite Eimeria, affecting a wide range of livestock species including poultry, cattle, swine, and sheep. This disease poses a substantial threat to the livestock industry, leading to reduced productivity, increased morbidity and mortality rates, and significant economic losses for farmers.

Several factors contribute to the increasing prevalence of coccidiosis globally. Firstly, the intensification of livestock production practices, characterized by higher stocking densities and increased contact between animals, creates favorable conditions for the transmission and spread of coccidia. Additionally, factors such as poor sanitation, inadequate biosecurity measures, and the reuse of contaminated bedding or litter can further exacerbate the prevalence of the disease.

Climate change and environmental factors also play a role in the rising prevalence of coccidiosis. Changes in temperature and humidity can create optimal conditions for the survival and proliferation of coccidia oocysts in the environment, increasing the risk of infection for susceptible animals. Globalization and the movement of livestock and poultry across regions and borders have facilitated the spread of coccidia to previously unaffected areas, contributing to the expansion of the disease's geographical range.

The increasing prevalence of drug-resistant strains of coccidia is another factor driving the demand for anticoccidial drugs. Over time, repeated exposure to anticoccidial drugs can lead to the development of resistance in coccidia populations, rendering traditional treatment options less effective. As a result, there is a growing need for new and innovative anticoccidial drugs with novel modes of action to combat drug-resistant strains and provide effective control of the disease.

Technological Advancements in Drug Development

Technological advancements in drug development have significantly contributed to the growth and innovation within the global anticoccidial drugs market. These advancements encompass a wide range of scientific and technological breakthroughs, including novel drug formulations, improved delivery systems, and enhanced understanding of the biology and pathogenesis of coccidiosis. One of the key areas of advancement in anticoccidial drug development is the introduction of novel formulations with improved efficacy and safety profiles. Pharmaceutical companies are investing in research and development to identify new drug candidates and optimize existing compounds to enhance their effectiveness against coccidia. This includes the development of next-generation anticoccidial drugs that target specific stages of the parasite life cycle or exploit vulnerabilities in coccidia metabolism, leading to more targeted and efficient treatment options.

Furthermore, advancements in drug delivery systems have revolutionized the way anticoccidial drugs are administered to animals. Traditional methods of drug administration, such as oral medications or medicated feed, are being complemented by innovative delivery technologies such as injectable formulations, slow-release implants, and medicated water systems. These delivery systems offer greater convenience, precision, and control over drug dosing, ensuring optimal efficacy while minimizing the risk of under- or overdosing.

Biotechnology and genetic engineering have also played a significant role in advancing the field of anticoccidial drug development. Researchers are leveraging techniques such as recombinant DNA technology and gene editing to produce recombinant proteins, antibodies, and vaccines targeting coccidia parasites. These biotechnological approaches offer novel strategies for disease control and prevention, including the development of genetically modified organisms with enhanced resistance to coccidiosis or the production of recombinant vaccines capable of inducing protective immunity against multiple strains of coccidia.

Advancements in high-throughput screening, bioinformatics, and computational modeling have accelerated the process of drug discovery and development, enabling researchers to identify potential drug candidates more rapidly and cost-effectively. This has led to an increase in the number of new anticoccidial drugs entering the market and expanded the range of treatment options available to farmers and veterinarians.

Key Market Challenges

Regulatory Constraints

One of the significant challenges hindering the global anticoccidial drugs market is regulatory constraints imposed by governmental bodies and regulatory agencies. These regulations often vary across different regions and countries, creating complexities for manufacturers seeking to gain approval for their products. Stringent requirements for safety, efficacy, and quality assurance necessitate extensive preclinical and clinical testing, which can be time-consuming and costly. Additionally, concerns over antimicrobial resistance have prompted regulatory agencies to impose restrictions on the use of certain classes of antimicrobials, including anticoccidial drugs, further limiting the availability and usage of these products in some markets. Navigating the regulatory landscape requires significant resources and expertise, posing a barrier to entry for smaller pharmaceutical companies and hindering innovation within the market.

Concerns Over Antimicrobial Resistance

Another key challenge facing the global anticoccidial drugs market is the growing concern over antimicrobial resistance. Prolonged and widespread use of antimicrobial agents, including anticoccidial drugs, can contribute to the development of resistant strains of coccidia parasites, rendering traditional treatment options less effective. This not only undermines the efficacy of existing drugs but also poses a threat to animal health and welfare. Furthermore, antimicrobial resistance has broader implications for public health, as resistant pathogens can be transmitted from animals to humans through the food chain or environmental contamination. As a result, there is increasing pressure from consumers, policymakers, and regulatory agencies to promote the responsible use of antimicrobials in livestock production and to develop alternative strategies for disease control that minimize the risk of resistance development.

Emerging Alternatives to Anticoccidial Drugs

The emergence of alternative strategies for coccidiosis control presents a challenge to the global anticoccidial drugs market. Advances in biotechnology, immunology, and microbiology have led to the development of alternative approaches such as vaccines, probiotics, prebiotics, and plant-derived compounds for preventing and managing coccidiosis in livestock. These alternatives offer potential advantages such as reduced risk of antimicrobial resistance, improved animal welfare, and enhanced consumer acceptance. As a result, there is growing interest and investment in these alternative solutions, leading to increased competition for market share within the anticoccidial drugs market.

Key Market Trends

Expansion Of Intensive Farming Practices Worldwide

With the global population steadily increasing and dietary preferences shifting towards protein-rich diets, there is a growing demand for livestock products such as meat, dairy, and eggs. To meet this demand, farmers are increasingly adopting intensive farming methods, characterized by high stocking densities and confined housing systems.

Intensive farming practices also create ideal conditions for the transmission and spread of diseases like coccidiosis. Coccidia parasites thrive in warm, humid environments, making densely populated livestock facilities particularly susceptible to outbreaks. Coccidiosis can cause significant economic losses for farmers due to decreased productivity, increased mortality rates, and the cost of treatment and prevention measures.

As a result, there is a rising demand for effective disease control measures, including anticoccidial drugs, to safeguard animal health and productivity in intensive farming operations. Anticoccidial drugs play a crucial role in preventing and managing coccidiosis by controlling the growth and spread of coccidia parasites in infected animals. By minimizing the incidence and severity of the disease, these drugs help farmers maintain optimal growth rates, feed conversion ratios, and overall productivity in their livestock herds.

The intensification of livestock production has led to increased awareness among farmers about the importance of disease prevention and management. Farmers recognize the significant impact that diseases like coccidiosis can have on their bottom line and are therefore willing to invest in preventive measures to protect their animals and ensure profitability. Anticoccidial drugs are a key component of these disease management strategies, providing farmers with a reliable and cost-effective solution for controlling coccidiosis in their herds.

The expansion of intensive farming practices is driving innovation within the anticoccidial drugs market. Pharmaceutical companies are investing in research and development to introduce new and improved formulations with enhanced efficacy, safety profiles, and modes of action. These advancements in drug development are enabling farmers to achieve better disease control outcomes and improve the overall health and welfare of their animals.

Focus on Animal Health and Welfare

The global anticoccidial drugs market is witnessing a notable boost due to an increasing focus on animal health and welfare. As consumer awareness grows regarding the conditions in which livestock are raised and the impact of farming practices on animal well-being, there is a corresponding demand for products and practices that promote healthier, happier animals. This focus on animal welfare has led to significant changes within the agricultural industry, including a heightened emphasis on disease prevention and management.

Coccidiosis, caused by protozoan parasites of the genus Eimeria, poses a significant threat to animal health and productivity, particularly in intensive farming operations. Infected animals can suffer from reduced growth rates, decreased feed efficiency, and increased mortality rates, leading to economic losses for farmers. In response, there has been a growing recognition of the importance of implementing effective disease control measures, such as the use of anticoccidial drugs, to safeguard animal health and welfare.

Anticoccidial drugs play a crucial role in preventing and controlling coccidiosis in livestock populations. By controlling the growth and spread of coccidia parasites, these drugs help to minimize the incidence and severity of the disease, thereby improving animal well-being and productivity. Farmers and livestock producers recognize the importance of maintaining healthy animals not only for ethical reasons but also for economic sustainability.

The focus on animal health and welfare extends beyond individual farm practices to encompass broader societal concerns about antibiotic resistance and food safety. There is increasing pressure from consumers, policymakers, and regulatory agencies to reduce the use of antibiotics in livestock production and to adopt alternative disease management strategies that prioritize animal welfare and environmental sustainability. In this context, anticoccidial drugs offer a valuable solution for controlling coccidiosis while minimizing the use of antibiotics in animal agriculture. These drugs are an essential tool for farmers seeking to maintain high standards of animal health and welfare while meeting the growing demand for sustainably produced meat, dairy, and eggs.

Segmental Insights

Drug Class Insights

Based on the drug class, the other drug classes emerged as the dominant segment in the global anticoccidial drugs market in 2023. Synthetic drugs are preferred by farmers and veterinarians for their reliability and convenience in disease management. These drugs are available in various formulations, including oral medications, feed additives, and water-soluble powders, allowing for flexible administration options tailored to the specific needs of different livestock species and production environments. Synthetic drugs are often more cost-effective compared to alternative treatment options such as vaccines or natural remedies, making them a practical choice for disease control in commercial livestock operations.

Drug Action Insights

Based on drug action, Coccidiostatic emerged as the dominant segment in the global anticoccidial drugs market in 2023. This is due to their ability to suppress parasite growth without eliminating them entirely, potentially reducing the likelihood of resistance development. Coccidiostatic drugs may offer a more sustainable approach, allowing for prolonged use while maintaining efficacy. This could appeal to farmers seeking long-term solutions for managing coccidiosis in their livestock, thus driving demand for coccidiostatic drugs in the market.

Regional Insights

North America emerged as the dominant player in the global anticoccidial drugs market in 2023, holding the largest market share. The region boasts a large and highly developed livestock industry, particularly in sectors such as poultry and cattle production. The intensive farming practices prevalent in North America create ideal conditions for the transmission and spread of diseases like coccidiosis, driving the demand for effective disease control measures such as anticoccidial drugs.

Key Market Players

Vetoquinol SA

Zoetis Philippines Inc

Phibro Animal Health Corporation

Huvepharma, Inc

Elanco US Inc.

Biochem Pharmaceutical Industries Ltd

Ceva Sante Animale SA

Impextraco NV

Boehringer Ingelheim International GmbH

Merck & Co., Inc.

Report Scope:

In this report, the Global Anticoccidial Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Anticoccidial Drugs Market, By Drug Class:

Ionophore Antibiotic Sulphonamides Chemical Derivative Other Drug Classes

Anticoccidial Drugs Market, By Drug Action:

Coccidiostatic Coccidiocidal

Anticoccidial Drugs Market, By Animal Type:

Production Animals Companion Animals

Anticoccidial Drugs Market, By Distribution Channel:

Veterinary Hospitals Retail Pharmacy Other Distribution Channels

Anticoccidial Drugs Market, By Region:

North America

United States

Canada

Mexico

Europe

France

United Kingdom

Italy

Germany

Spain

Asia-Pacific

China

India

Japan

Australia

South Korea

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Anticoccidial Drugs Market.

Available Customizations:

Global Anticoccidial Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customers

5. Global Anticoccidial Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Class (Ionophore, Antibiotic, Sulphonamides, Chemical Derivative, Other Drug Classes)
  • 5.2.2. By Drug Action (Coccidiostatic, Coccidiocidal)
  • 5.2.3. By Animal Type (Production Animals, Companion Animals)
  • 5.2.4. By Distribution Channel (Veterinary Hospitals, Retail Pharmacy, Other Distribution Channels)
  • 5.2.5. By Region
  • 5.2.6. By Company (2023)
• 5.3. Market Map
  • 5.3.1. By Drug Class
  • 5.3.2. By Drug Action
  • 5.3.3. By Animal Type
  • 5.3.4. By Distribution Channel
  • 5.3.5. By Region

6. Asia Pacific Anticoccidial Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Class
  • 6.2.2. By Drug Action
  • 6.2.3. By Animal Type
  • 6.2.4. By Distribution Channel
  • 6.2.5. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Anticoccidial Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Class
      • 6.3.1.2.2. By Drug Action
      • 6.3.1.2.3. By Animal Type
      • 6.3.1.2.4. By Distribution Channel
  • 6.3.2. India Anticoccidial Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Class
      • 6.3.2.2.2. By Drug Action
      • 6.3.2.2.3. By Animal Type
      • 6.3.2.2.4. By Distribution Channel
  • 6.3.3. Australia Anticoccidial Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Class
      • 6.3.3.2.2. By Drug Action
      • 6.3.3.2.3. By Animal Type
      • 6.3.3.2.4. By Distribution Channel
  • 6.3.4. Japan Anticoccidial Drugs Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Drug Class
      • 6.3.4.2.2. By Drug Action
      • 6.3.4.2.3. By Animal Type
      • 6.3.4.2.4. By Distribution Channel
  • 6.3.5. South Korea Anticoccidial Drugs Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Drug Class
      • 6.3.5.2.2. By Drug Action
      • 6.3.5.2.3. By Animal Type
      • 6.3.5.2.4. By Distribution Channel

7. Europe Anticoccidial Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Class
  • 7.2.2. By Drug Action
  • 7.2.3. By Animal Type
  • 7.2.4. By Distribution Channel
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Anticoccidial Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Class
      • 7.3.1.2.2. By Drug Action
      • 7.3.1.2.3. By Animal Type
      • 7.3.1.2.4. By Distribution Channel
  • 7.3.2. Germany Anticoccidial Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Class
      • 7.3.2.2.2. By Drug Action
      • 7.3.2.2.3. By Animal Type
      • 7.3.2.2.4. By Distribution Channel
  • 7.3.3. Spain Anticoccidial Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Class
      • 7.3.3.2.2. By Drug Action
      • 7.3.3.2.3. By Animal Type
      • 7.3.3.2.4. By Distribution Channel
  • 7.3.4. Italy Anticoccidial Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Class
      • 7.3.4.2.2. By Drug Action
      • 7.3.4.2.3. By Animal Type
      • 7.3.4.2.4. By Distribution Channel
  • 7.3.5. United Kingdom Anticoccidial Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Class
      • 7.3.5.2.2. By Drug Action
      • 7.3.5.2.3. By Animal Type
      • 7.3.5.2.4. By Distribution Channel

8. North America Anticoccidial Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Class
  • 8.2.2. By Drug Action
  • 8.2.3. By Animal Type
  • 8.2.4. By Distribution Channel
  • 8.2.5. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Anticoccidial Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Class
      • 8.3.1.2.2. By Drug Action
      • 8.3.1.2.3. By Animal Type
      • 8.3.1.2.4. By Distribution Channel
  • 8.3.2. Mexico Anticoccidial Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Class
      • 8.3.2.2.2. By Drug Action
      • 8.3.2.2.3. By Animal Type
      • 8.3.2.2.4. By Distribution Channel
  • 8.3.3. Canada Anticoccidial Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Class
      • 8.3.3.2.2. By Type
      • 8.3.3.2.3. By Animal Type
      • 8.3.3.2.4. By Distribution Channel

9. South America Anticoccidial Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Class
  • 9.2.2. By Drug Action
  • 9.2.3. By Animal Type
  • 9.2.4. By Distribution Channel
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Anticoccidial Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Class
      • 9.3.1.2.2. By Drug Action
      • 9.3.1.2.3. By Animal Type
      • 9.3.1.2.4. By Distribution Channel
  • 9.3.2. Argentina Anticoccidial Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Class
      • 9.3.2.2.2. By Drug Action
      • 9.3.2.2.3. By Animal Type
      • 9.3.2.2.4. By Distribution Channel
  • 9.3.3. Colombia Anticoccidial Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Class
      • 9.3.3.2.2. By Drug Action
      • 9.3.3.2.3. By Animal Type
      • 9.3.3.2.4. By Distribution Channel

10. Middle East and Africa Anticoccidial Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Class
  • 10.2.2. By Drug Action
  • 10.2.3. By Animal Type
  • 10.2.4. By Distribution Channel
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Anticoccidial Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Class
      • 10.3.1.2.2. By Drug Action
      • 10.3.1.2.3. By Animal Type
      • 10.3.1.2.4. By Distribution Channel
  • 10.3.2. Saudi Arabia Anticoccidial Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Class
      • 10.3.2.2.2. By Drug Action
      • 10.3.2.2.3. By Animal Type
      • 10.3.2.2.4. By Distribution Channel
  • 10.3.3. UAE Anticoccidial Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Class
      • 10.3.3.2.2. By Drug Action
      • 10.3.3.2.3. By Animal Type
      • 10.3.3.2.4. By Distribution Channel
  • 10.3.4. Egypt Anticoccidial Drugs Market Outlook
    • 10.3.4.1. Market Size & Forecast
      • 10.3.4.1.1. By Value
    • 10.3.4.2. Market Share & Forecast
      • 10.3.4.2.1. By Drug Class
      • 10.3.4.2.2. By Drug Action
      • 10.3.4.2.3. By Animal Type
      • 10.3.4.2.4. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Anticoccidial Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. Competitive Landscape

• 15.1. Vetoquinol SA
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (In case of listed)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Zoetis Philippines Inc
• 15.3. Phibro Animal Health Corporation
• 15.4. Huvepharma, Inc
• 15.5. Elanco US Inc.
• 15.6. Biochem Pharmaceutical Industries Ltd
• 15.7. Ceva Sante Animale SA
• 15.8. Impextraco NV
• 15.9. Boehringer Ingelheim International GmbH
• 15.10. Merck & Co., Inc.

16. Strategic Recommendations

17. About Us & Disclaimer